Sponsors (2)
The bill clarifies and retroactively affirms podiatrists' federal authority to register for and prescribe controlled substances—improving access and legal protection for patient care—while modestly increasing diversion risk and imposing reconciliation burdens on regulators and registrants.
Podiatrists (WHO) are explicitly authorized under federal law to register for and prescribe controlled substances (WHAT), clarifying their prescribing authority and improving patient access to necessary medications for foot/ankle and chronic conditions.
The law's retroactive effective date (Dec 29, 2022) (WHAT) validates prior podiatrist registrations and prescriptions back to that date, reducing the risk that past patient care will be treated as noncompliant and protecting clinicians and patients from retrospective penalties.
By explicitly adding podiatrists as authorized prescribers (WHAT), the bill may modestly increase overall access to controlled substances and therefore raises the risk of diversion or misuse.
Making the change retroactive to Dec 29, 2022 (WHAT) could create legal uncertainty and administrative burden for the DEA and registrants who must reconcile prior registrations and prescribing actions with the amended statutory text.
Based on analysis of 2 sections of legislative text.
Introduced March 11, 2025 by Michael F. Bennet · Last progress March 11, 2025
Adds "podiatric medicine" into the controlled-substances registration statute's list of medical curricula references and makes small wording and punctuation edits to that same provision. The technical changes are applied retroactively to December 29, 2022, and affect the statutory text used to determine practitioner registration requirements for prescribing controlled substances.